Generation of Rat Monoclonal Antibodies Against Human Epidermal Growth Factor Receptor 2.

Monoclon Antib Immunodiagn Immunother

Department of Applied Chemistry and Bioengineering, Graduate School of Engineering, Osaka City University, Osaka-shi, Japan.

Published: April 2023

AI Article Synopsis

  • HER2 is a transmembrane receptor involved in cell growth and survival, playing a key role in various cancers, especially breast cancer, by promoting cell proliferation and preventing cell death.
  • Trastuzumab and pertuzumab are targeted therapies that focus on HER2, using monoclonal antibodies to block its action, aiming to treat HER2-overexpressing tumors.
  • This study focuses on developing rat monoclonal antibodies against the extracellular domain of HER2, utilizing the SK-BR-3 breast cancer cell line to test their effectiveness in detecting HER2.

Article Abstract

Human epidermal growth factor receptor 2 (HER2) is a transmembrane tyrosine kinase receptor without any known ligands and a member of the epidermal growth factor receptor (EGFR) family. It is a proto-oncogenic protein that, through signaling cascades, promotes cell proliferation and inhibits apoptosis in cancer cells through homo- and heterodimerization with other EGFR family receptors. Since several cancers, including breast cancer, overexpress HER2, it is a target of tumor therapy. Both trastuzumab and pertuzumab are recombinant humanized monoclonal antibodies (mAbs) used in clinical trials that target the extracellular domain (ECD) of HER2. Therefore, it is important to generate antibodies against various ECDs of HER2. In this study, we describe rat mAbs, which were generated against the ECD of human HER2. The human breast cancer cell line SK-BR-3 was subjected to immunofluorescence staining as it expresses HER2, and mAbs can detect both intact and endogenous HER2 within the cell line.

Download full-text PDF

Source
http://dx.doi.org/10.1089/mab.2022.0042DOI Listing

Publication Analysis

Top Keywords

epidermal growth
12
growth factor
12
factor receptor
12
monoclonal antibodies
8
human epidermal
8
egfr family
8
breast cancer
8
her2
7
generation rat
4
rat monoclonal
4

Similar Publications

Background: The RELAY-Brain trial examined the clinical utility and survival impacts of ramucirumab (RAM) combined with epidermal growth factor receptor (EGFR)-TKI in patients with EGFR-mutated non-small-cell lung cancer (NSCLC) with brain metastases. Although RAM combined with erlotinib (ERL) is known to have clinical benefits, the benefits in patients with baseline brain metastases remain unclear. This report examined the long-term follow-up data (Japan Registry of Clinical Trials: jRCTs2051190027) of the same patients, analyzing relevant biomarkers from tumor and plasma samples.

View Article and Find Full Text PDF

Uncommon atypical mutations account for 10-15% of all epidermal growth factor receptor (EGFR) activating mutations in nonsmall-cell lung cancer (NSCLC). Tumors harboring rare EGFR mutations show highly heterogeneous responses to EGFR tyrosine kinase inhibitors (TKIs). There is insufficient clinical evidence for uncommon types of EGFR mutations, especially those with compound EGFR mutations.

View Article and Find Full Text PDF

Aims: Limited studies have been conducted on juvenile conjunctival nevus (JCN) in Asian populations. This study aims to investigate the clinical and pathologic characteristics of JCN cases among the Han ethnicity in northwest China, providing insights for pathologists and ophthalmologists in diagnosing this condition.

Methods: A subset of conjunctival nevi in children and adolescents, characterized by a confluent growth pattern and lack of maturation, was identified and defined as JCN.

View Article and Find Full Text PDF

Background: Recent studies have shown that receptor status of breast cancer change between primary tumor and recurrence, which may influence treatment strategy and prognosis, but there are few reports on receptor discordance between primary tumors and local recurrence (LR) after nipple-sparing mastectomy (NSM).

Patients And Methods: We collected 74 patients who had LR after NSM for newly diagnosed stages 0 to 3 breast cancer between 2008 and 2016 at 14 institutions. We classified into 4 subtypes based on hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2).

View Article and Find Full Text PDF

Leaf vein, an essential part of leaf architecture, plays significant roles in shaping the proper leaf size. To date, the molecular mechanisms governing leaf development including leaf venation patterning remains poorly understood in birch. Here, we performed the genome-wide identification of homeodomain-like (HD-like) superfamily genes using phylogenetic analysis and revealed the functional role of a potential HD-like gene in leaf growth and development using transgenic technology and transcriptomic sequencing.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!